| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rare Diseases | 3 | 2020 | 351 | 0.870 |
Why?
|
| Genes, erbB-2 | 5 | 2007 | 229 | 0.610 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2020 | 3251 | 0.610 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 1249 | 0.560 |
Why?
|
| Receptor, ErbB-2 | 6 | 2021 | 2518 | 0.470 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 10331 | 0.420 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2021 | 1215 | 0.400 |
Why?
|
| Gene Amplification | 5 | 2007 | 731 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2022 | 507 | 0.330 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2019 | 992 | 0.290 |
Why?
|
| Breast Neoplasms | 13 | 2021 | 15694 | 0.280 |
Why?
|
| Neoplasms | 4 | 2020 | 15193 | 0.220 |
Why?
|
| Cell Cycle Proteins | 3 | 2021 | 2045 | 0.210 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2021 | 521 | 0.210 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2015 | 1216 | 0.200 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2021 | 16 | 0.200 |
Why?
|
| Oxadiazoles | 1 | 2021 | 57 | 0.200 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 253 | 0.180 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2021 | 311 | 0.180 |
Why?
|
| PHD Zinc Fingers | 1 | 2019 | 4 | 0.180 |
Why?
|
| Anilides | 1 | 2021 | 268 | 0.170 |
Why?
|
| Metabolome | 1 | 2021 | 344 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2022 | 428 | 0.160 |
Why?
|
| Histone Code | 1 | 2019 | 79 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2011 | 2232 | 0.150 |
Why?
|
| Heterografts | 1 | 2020 | 733 | 0.150 |
Why?
|
| Observer Variation | 2 | 2016 | 671 | 0.150 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 172 | 0.150 |
Why?
|
| Prognosis | 11 | 2021 | 21713 | 0.150 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 223 | 0.150 |
Why?
|
| Biopsy | 2 | 2020 | 3443 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 10035 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2012 | 1143 | 0.140 |
Why?
|
| Piperidines | 1 | 2021 | 1035 | 0.140 |
Why?
|
| Phthalazines | 1 | 2017 | 253 | 0.130 |
Why?
|
| beta Catenin | 1 | 2019 | 688 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 358 | 0.130 |
Why?
|
| Receptors, Estrogen | 2 | 2021 | 2086 | 0.130 |
Why?
|
| Disease Progression | 4 | 2020 | 6682 | 0.130 |
Why?
|
| Mitotic Index | 1 | 2015 | 162 | 0.130 |
Why?
|
| Pathology, Clinical | 1 | 2016 | 152 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 493 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2021 | 2488 | 0.120 |
Why?
|
| Pyridines | 1 | 2021 | 1244 | 0.120 |
Why?
|
| Female | 24 | 2022 | 141928 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 1033 | 0.120 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 29902 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 2054 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 1823 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 854 | 0.120 |
Why?
|
| Cell Proliferation | 4 | 2021 | 7226 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 666 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1026 | 0.110 |
Why?
|
| Tissue Array Analysis | 3 | 2015 | 760 | 0.110 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 1022 | 0.110 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 7222 | 0.110 |
Why?
|
| Transcription Factor RelA | 1 | 2012 | 184 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1586 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2022 | 3821 | 0.100 |
Why?
|
| Histones | 1 | 2019 | 1466 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 5437 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2054 | 0.100 |
Why?
|
| Aged | 13 | 2020 | 70117 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1866 | 0.100 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 3578 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2019 | 1341 | 0.090 |
Why?
|
| Humans | 27 | 2022 | 261506 | 0.090 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2011 | 204 | 0.090 |
Why?
|
| Receptors, Androgen | 1 | 2015 | 878 | 0.090 |
Why?
|
| Breast | 2 | 2015 | 1344 | 0.090 |
Why?
|
| Middle Aged | 13 | 2020 | 86204 | 0.090 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 3230 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2022 | 4307 | 0.080 |
Why?
|
| Adult | 12 | 2020 | 77950 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 4757 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 3552 | 0.080 |
Why?
|
| Estradiol | 1 | 2011 | 748 | 0.080 |
Why?
|
| Cell Line, Tumor | 6 | 2021 | 14551 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 1226 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2012 | 611 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5178 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2014 | 977 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 2 | 2007 | 1165 | 0.070 |
Why?
|
| Apoptosis | 3 | 2021 | 7591 | 0.070 |
Why?
|
| Proto-Oncogenes | 1 | 2006 | 202 | 0.070 |
Why?
|
| Gene Deletion | 1 | 2011 | 1442 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2015 | 7548 | 0.070 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 4844 | 0.070 |
Why?
|
| Mice | 6 | 2022 | 34495 | 0.060 |
Why?
|
| Neoplasm Staging | 7 | 2019 | 13658 | 0.060 |
Why?
|
| Young Adult | 2 | 2020 | 21445 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2004 | 275 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2007 | 696 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 8873 | 0.060 |
Why?
|
| Animals | 7 | 2022 | 59536 | 0.060 |
Why?
|
| Quality Control | 1 | 2004 | 457 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2014 | 2967 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5112 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 1833 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 2104 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2004 | 299 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 4849 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 479 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2022 | 348 | 0.050 |
Why?
|
| Male | 5 | 2020 | 123000 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 14889 | 0.050 |
Why?
|
| Microarray Analysis | 2 | 2012 | 392 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 15862 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6009 | 0.050 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2021 | 278 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 371 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 550 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 32848 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 615 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 555 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 4367 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 3981 | 0.040 |
Why?
|
| Acrylonitrile | 1 | 2017 | 8 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2022 | 848 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 1313 | 0.040 |
Why?
|
| Mutation | 3 | 2021 | 15179 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2022 | 2314 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 1082 | 0.040 |
Why?
|
| Survival Rate | 3 | 2020 | 12221 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2019 | 575 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2017 | 177 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2019 | 1008 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2019 | 430 | 0.030 |
Why?
|
| International Agencies | 1 | 2016 | 107 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 2315 | 0.030 |
Why?
|
| Cadherins | 1 | 2019 | 660 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 1519 | 0.030 |
Why?
|
| Genes, erbB-1 | 2 | 2006 | 101 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 657 | 0.030 |
Why?
|
| Pathologists | 1 | 2016 | 91 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1742 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 986 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 339 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 5395 | 0.030 |
Why?
|
| Genes, myc | 2 | 2006 | 358 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3472 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 973 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 479 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 4938 | 0.030 |
Why?
|
| Cyclin D1 | 2 | 2005 | 576 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 2508 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2012 | 226 | 0.030 |
Why?
|
| Androgens | 1 | 2015 | 511 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Caspases, Initiator | 1 | 2011 | 16 | 0.030 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2011 | 65 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 297 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2011 | 118 | 0.020 |
Why?
|
| Genotype | 1 | 2019 | 4109 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 14289 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 1546 | 0.020 |
Why?
|
| Protein Folding | 1 | 2011 | 281 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 2738 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2012 | 250 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 700 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5159 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2011 | 448 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 621 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 1301 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2019 | 37905 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 778 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9244 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 2074 | 0.020 |
Why?
|
| Cyclin D | 1 | 2006 | 37 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2006 | 109 | 0.020 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2006 | 116 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 3842 | 0.020 |
Why?
|
| Switzerland | 1 | 2005 | 21 | 0.020 |
Why?
|
| Saudi Arabia | 1 | 2005 | 39 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 1392 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 2173 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 1946 | 0.020 |
Why?
|
| Cyclins | 1 | 2006 | 456 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 4804 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 3154 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 501 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 2370 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 11965 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 17523 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2004 | 829 | 0.010 |
Why?
|
| Epithelium | 1 | 2004 | 720 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6207 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2011 | 2819 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2005 | 810 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 10001 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 1506 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 1910 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 7551 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 2283 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 4298 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2005 | 2295 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 7789 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 9180 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 3343 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 4821 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 5539 | 0.010 |
Why?
|